BioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform

Executive Summary

• BioNxt announced a major expansion of its global patent portfolio covering its sublingual cladribine ODF platform, including a European Patent granted for up to 39 EPC states and an Eurasian patent covering eight countries.
• The company filed a USPTO “Track One” fast‑track application, accelerating U.S. examination and positioning BioNxt for near‑term licensing and partnership discussions.
• With the strengthened IP estate, BioNxt is transitioning into commercialization, actively pursuing licensing, co‑development, and royalty‑based supply agreements for its platform in neurology and autoimmune indications.

Key Details

• European Patent No. 4539857 granted on March 11 2026, covering ODF technology across up to 39 EPC member states.
• Eurasian Patent No. 051510 granted on November 14 2025, protecting the technology in eight Eurasian jurisdictions (including Russia and Kazakhstan).
• U.S. Track One filing: accelerated “fast‑track” patent application submitted to USPTO; expected final disposition within 9–12 months.
• PCT national phase applications progressing in Canada, Japan, Australia, and New Zealand.
• Combined addressable market of ≈1 billion people, enhancing long‑term exclusivity and global licensing potential.
• Platform covers formulation, manufacturing processes, administration methods, and therapeutic applications for MS, MG, lupus nephritis, and other neuro‑degenerative/autoimmune diseases.
• BioNxt is moving to a partner‑driven commercialization model: seeking licensing agreements, co‑development collaborations, and royalty‑based supply arrangements with pharmaceutical partners.
• CEO Hugh Rogers highlighted the “defining moment” created by the expanded IP estate and accelerated U.S. pathway, emphasizing focus on translating IP strength into strategic partnerships and revenue streams.

Notable Quotes

“We have reached a defining moment for BioNxt,” said Hugh Rogers, CEO of BioNxt Solutions Inc. “Our global patent estate, combined with the accelerated U.S. pathway, provides the foundation to move decisively into commercialization. We are now focused on translating our IP strength into strategic partnerships and long‑term revenue opportunities.”